VAXIL BIO LTD., an innovative immunotherapy biotech focused on cancer and infectious diseases, is pleased to announce that the closing date for the previously announced non-brokered private placement of up to 18,750,000 common shares at a price of CDN$0.04 per share for gross proceeds of up to CDN$750,000 has been extended and is expected to close on or about November 15, 2019.
October 30, 2019
· 3 min read